This medicine may mask or delay the symptoms of syphilis. It is not effective against syphilis infections. Azithromycin belongs to the class of drugs known as macrolide antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:.
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. Appropriate studies have not been performed on the relationship of age to the effects of azithromycin to treat sinusitis in children or to treat pneumonia in children younger than 6 months of age.
Safety and efficacy have not been established in these age groups. Appropriate studies have not been performed on the relationship of age to the effects of azithromycin oral suspension and tablets to treat pharyngitis or tonsillitis in children younger than 2 years of age. Safety and efficacy have not been established. Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of azithromycin in the elderly.
However, elderly patients are more likely to have heart rhythm problems eg, torsades de pointes which may require caution in patients receiving azithromycin. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.
In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive. Using this medicine with any of the following medicines is not recommended.
Your doctor may decide not to treat you with this medication or change some of the other medicines you take. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases.
If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. The presence of other medical problems may affect the use of this medicine.
Make sure you tell your doctor if you have any other medical problems, especially:. Take this medicine only as directed by your doctor.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing. After water has been added to the powder, use the dose within 12 hours and throw away any unused liquid after your dose. Do not freeze the bottle. Do not keep the oral liquid for more than 10 days. Throw away any unused liquid after all doses are completed.
There is a problem with information submitted for this request. Sign up for free, and stay up-to-date on research advancements, health tips and current health topics, like COVID, plus expert advice on managing your health. Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information and to understand which information is beneficial, we may combine your e-mail and website usage information with other information we have about you.
If we combine this information with your PHI, we will treat all of that information as PHI, and will only use or disclose that information as set forth in our notice of privacy practices.
You may opt-out of e-mail communications at any time by clicking on the Unsubscribe link in the e-mail. Our Housecall e-newsletter will keep you up-to-date on the latest health information. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Foscarnet: Major Avoid coadministration of azithromycin with foscarnet due to the increased risk of QT prolongation. Both QT prolongation and TdP have been reported during postmarketing use of foscarnet.
Fosphenytoin: Minor Until more data are available, the manufacturer of azithromycin recommends caution and careful monitoring of patients who receive azithromycin with fosphenytoin. Azithromycin was not implicated in clinical trials with drug interactions with fosphenytoin. However, specific drug interaction studies have not been performed with the combination of azithromycin and fosphenytoin. Fostemsavir: Major Avoid coadministration of azithromycin with fostemsavir due to the increased risk of QT prolongation.
Supratherapeutic doses of fostemsavir 2, mg twice daily, four times the recommended daily dose have been shown to cause QT prolongation. Fostemsavir causes dose-dependent QT prolongation. Gemifloxacin: Major Avoid coadministration of azithromycin with gemifloxacin due to the increased risk of QT prolongation.
Gemifloxacin may also prolong the QT interval in some patients. The maximal change in the QTc interval occurs approximately 5 to 10 hours following oral administration of gemifloxacin.
The likelihood of QTc prolongation may increase with increasing dose of the drug; therefore, the recommended dose should not be exceeded especially in patients with renal or hepatic impairment where the Cmax and AUC are slightly higher. Gemtuzumab Ozogamicin: Major Avoid coadministration of azithromycin with gemtuzumab due to the increased risk of QT prolongation.
Although QT interval prolongation has not been reported with gemtuzumab, it has been reported with other drugs that contain calicheamicin. Gilteritinib: Major Avoid coadministration of azithromycin with gilteritinib due to the increased risk of QT prolongation. Gilteritinib has been associated with QT prolongation. Glasdegib: Major Avoid coadministration of azithromycin with glasdegib due to the increased risk of QT prolongation. Glasdegib therapy may result in QT prolongation and ventricular arrhythmias including ventricular fibrillation and ventricular tachycardia.
Glycopyrrolate; Formoterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Goserelin: Major Avoid coadministration of azithromycin with goserelin due to the increased risk of QT prolongation. Granisetron: Major Avoid coadministration of azithromycin with granisetron due to the increased risk of QT prolongation. Granisetron has been associated with QT prolongation. Halogenated Anesthetics: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation.
Haloperidol: Major Avoid coadministration of azithromycin with haloperidol due to the increased risk of QT prolongation. Excessive doses particularly in the overdose setting or IV administration of haloperidol may be associated with a higher risk of QT prolongation. Halothane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. Histrelin: Major Avoid coadministration of azithromycin with histrelin due to the increased risk of QT prolongation.
Hydroxychloroquine: Major Avoid coadministration of hydroxychloroquine and azithromycin due the risk of additive QT prolongation. Hydroxychloroquine prolongs the QT interval. QT prolongation and torsade de pointe TdP have been spontaneously reported during azithromycin postmarketing surveillance. Hydroxyzine: Major Avoid coadministration of azithromycin with hydroxyzine due to the increased risk of QT prolongation.
Postmarketing data indicate that hydroxyzine causes QT prolongation and TdP. Ibutilide: Major Avoid coadministration of azithromycin with ibutilide due to the increased risk of QT prolongation. Ibutilide administration can cause QT prolongation and TdP; proarrhythmic events should be anticipated.
The potential for proarrhythmic events with ibutilide increases with the coadministration of other drugs that prolong the QT interval. Iloperidone: Major Avoid coadministration of azithromycin with iloperidone due to the increased risk of QT prolongation.
Iloperidone has been associated with QT prolongation. Imipramine: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Indacaterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.
Indacaterol; Glycopyrrolate: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.
Inotuzumab Ozogamicin: Major Avoid coadministration of inotuzumab ozogamicin with azithromycin due to the potential for additive QT interval prolongation and risk of torsade de pointes TdP. If coadministration is unavoidable, obtain an ECG and serum electrolytes prior to the start of treatment, after treatment initiation, and periodically during treatment. Avoid any non-essential QT prolonging drugs and correct electrolyte imbalances. Inotuzumab has been associated with QT interval prolongation.
QT prolongation and TdP have been spontaneously reported during azithromycin postmarketing surveillance. Ipratropium; Albuterol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Isoflurane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation.
Itraconazole: Major Avoid coadministration of azithromycin with itraconazole due to the increased risk of QT prolongation. Itraconazole has been associated with prolongation of the QT interval. Ivosidenib: Major Avoid coadministration of azithromycin with ivosidenib due to an increased risk of QT prolongation.
An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs. Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. Ketoconazole: Major Avoid coadministration of azithromycin with ketoconazole due to the increased risk of QT prolongation. Ketoconazole has been associated with prolongation of the QT interval. Lapatinib: Major Avoid coadministration of azithromycin with lapatinib due to the increased risk of QT prolongation.
Lapatinib has been associated with concentration-dependent QT prolongation; ventricular arrhythmias and TdP have been reported in postmarketing experience with lapatinib. Lefamulin: Major Avoid coadministration of azithromycin with lefamulin as concurrent use may increase the risk of QT prolongation.
Lefamulin has a concentration dependent QTc prolongation effect. The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between lefamulin and other drugs that effect cardiac conduction is unknown. Lenvatinib: Major Avoid coadministration of azithromycin with lenvatinib due to the increased risk of QT prolongation.
Prolongation of the QT interval has been reported with lenvatinib therapy. Leuprolide: Major Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT prolongation. Leuprolide; Norethindrone: Major Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT prolongation. Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Levalbuterol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Levofloxacin: Major Avoid coadministration of azithromycin with levofloxacin due to the increased risk of QT prolongation. Levofloxacin has been associated with a risk of QT prolongation and TdP. Although extremely rare, TdP has been reported during postmarketing surveillance of levofloxacin. Levonorgestrel: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Levonorgestrel; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Levonorgestrel; Ethinyl Estradiol; Ferrous Bisglycinate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Lithium: Major Avoid coadministration of azithromycin with lithium due to the increased risk of QT prolongation. Lithium has also been associated with QT prolongation. Lofexidine: Major Avoid coadministration of azithromycin with lofexidine due to the increased risk of QT prolongation.
Lofexidine prolongs the QT interval. Long-acting beta-agonists: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation. Loperamide: Major Avoid coadministration of azithromycin with loperamide due to the increased risk of QT prolongation. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest.
Loperamide; Simethicone: Major Avoid coadministration of azithromycin with loperamide due to the increased risk of QT prolongation. Lopinavir; Ritonavir: Major Avoid coadministration of azithromycin with lopinavir; ritonavir due to the increased risk of QT prolongation. Lopinavir; ritonavir is associated with QT prolongation. Macimorelin: Major Avoid coadministration of azithromycin with macimorelin due to the increased risk of QT prolongation and torsade de pointes-type ventricular tachycardia.
Sufficient washout time of drugs that are known to prolong the QT interval prior to administration of macimorelin is recommended. Treatment with macimorelin has been associated with an increase in the corrected QT QTc interval. Maprotiline: Major Avoid coadministration of azithromycin with maprotiline due to the increased risk of QT prolongation. Maprotiline has been reported to prolong the QT interval, particularly in overdose or with higher-dose prescription therapy elevated serum concentrations.
Cases of long QT syndrome and TdP tachycardia have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and in the absence of other known risk factors for QT prolongation.
Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. Mefloquine: Major Avoid coadministration of azithromycin with mefloquine due to the increased risk of QT prolongation.
There is evidence that the use of halofantrine after mefloquine causes a significant lengthening of the QTc interval. Mefloquine alone has not been reported to cause QT prolongation. Meperidine; Promethazine: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. Mestranol; Norethindrone: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Metaproterenol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Methadone: Major Avoid coadministration of azithromycin with methadone due to the increased risk of QT prolongation.
Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Midostaurin: Major Avoid coadministration of azithromycin with midostaurin due to the increased risk of QT prolongation. QT prolongation was reported in patients who received midostaurin in clinical trials.
Mifepristone: Major Avoid coadministration of azithromycin with mifepristone due to the increased risk of QT prolongation. Mifepristone has been associated with dose-dependent prolongation of the QT interval. Mirtazapine: Major Avoid coadministration of azithromycin with mirtazapine due to the increased risk of QT prolongation.
Mirtazapine has been associated with dose-dependent prolongation of the QT interval. TdP has been reported postmarketing, primarily in overdose or in patients with other risk factors for QT prolongation.
Moxifloxacin: Major Avoid coadministration of azithromycin with moxifloxacin due to the increased risk of QT prolongation. Quinolones have been associated with a risk of QT prolongation. Although extremely rare, TdP has been reported during postmarketing surveillance of moxifloxacin. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory. Nelfinavir: Moderate Coadministration of nelfinavir and azithromycin results in increased azithromycin concentrations.
Dosage adjustments are not necessary, although patients should be monitored for azithromycin related adverse effects such as increased hepatic enzymes and hearing impairment. Nilotinib: Major Avoid coadministration of azithromycin with nilotinib due to the increased risk of QT prolongation. Sudden death and QT prolongation have been reported in patients who received nilotinib therapy. Norethindrone Acetate; Ethinyl Estradiol; Ferrous fumarate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Norethindrone: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Norethindrone; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Norethindrone; Ethinyl Estradiol; Ferrous fumarate: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Norgestimate; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics.
Norgestrel: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Nortriptyline: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Octreotide: Major Avoid coadministration of azithromycin with octreotide due to the increased risk of QT prolongation. Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy.
Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the QT interval. Ofloxacin: Major Avoid coadministration of azithromycin with ofloxacin due to the increased risk of QT prolongation.
Quinolones have been associated with a risk of QT prolongation and TdP. Although extremely rare, TdP has been reported during postmarketing surveillance of ofloxacin. Olanzapine: Major Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval.
Olanzapine; Fluoxetine: Major Avoid coadministration of azithromycin with fluoxetine due to the increased risk of QT prolongation. Major Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation.
Olanzapine; Samidorphan: Major Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT prolongation. Olodaterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.
Ondansetron: Major Avoid coadministration of azithromycin with ondansetron due to the increased risk of QT prolongation. Ondansetron has been associated with a dose-related increase in the QT interval and postmarketing reports of TdP.
Oral Contraceptives: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Osilodrostat: Major Avoid coadministration of azithromycin with osilodrostat due to the increased risk of QT prolongation.
Osilodrostat is associated with dose-dependent QT prolongation. Osimertinib: Major Avoid coadministration of azithromycin with osimertinib if possible due to the risk of QT prolongation and torsade de pointes TdP. An interruption of osimertinib therapy with dose reduction or discontinuation may be necessary if QT prolongation occurs.
Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib. Oxaliplatin: Major Avoid coadministration of azithromycin with oxaliplatin due to the increased risk of QT prolongation. QT prolongation and ventricular arrhythmias including fatal TdP have been reported with oxaliplatin use in postmarketing experience. Ozanimod: Major Avoid coadministration of azithromycin with ozanimod due to the increased risk of QT prolongation.
Ozanimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ozanimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia.
Paliperidone: Major Avoid coadministration of azithromycin with paliperidone due to the increased risk of QT prolongation. Paliperidone has been associated with QT prolongation; torsade de pointes and ventricular fibrillation have been reported in the setting of overdose. Panobinostat: Major Avoid coadministration of azithromycin with panobinostat due to the increased risk of QT prolongation. QT prolongation has been reported with panobinostat.
Pasireotide: Major Avoid coadministration of azithromycin with pasireotide due to the increased risk of QT prolongation. QT prolongation has also occurred with pasireotide at therapeutic and supra-therapeutic doses.
Pazopanib: Major Avoid coadministration of azithromycin with pazopanib due to the increased risk of QT prolongation. Pazopanib has been reported to prolong the QT interval.
Pentamidine: Major Avoid coadministration of azithromycin with pentamidine due to the increased risk of QT prolongation. Systemic pentamidine has been associated with QT prolongation. Perphenazine: Major Avoid coadministration of azithromycin with perphenazine due to the increased risk of QT prolongation.
Perphenazine is associated with a possible risk for QT prolongation. Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. Perphenazine; Amitriptyline: Major Avoid coadministration of azithromycin with perphenazine due to the increased risk of QT prolongation. Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation.
Phenytoin: Minor Until more data are available, the manufacturer of azithromycin recommends caution and careful monitoring of patients who receive azithromycin with phenytoin. Azithromycin was not implicated in clinical trials with drug interactions with phenytoin.
However, specific drug interaction studies have not been performed with the combination of azithromycin and phenytoin. Pimavanserin: Major Avoid coadministration of azithromycin with pimavanserin due to the increased risk of QT prolongation. Pimavanserin prolongs the QT interval.
Pimozide: Contraindicated Pimozide is associated with a well-established risk of QT prolongation and torsade de pointes TdP.
Because of the potential for TdP, use of macrolide antibiotics with pimozide is contraindicated. Pirbuterol: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Pitolisant: Major Avoid coadministration of azithromycin with pitolisant due to the increased risk of QT prolongation. Pitolisant prolongs the QT interval. Ponesimod: Major Avoid coadministration of azithromycin with ponesimod due to the increased risk of QT prolongation.
Ponesimod initiation may result in a transient decrease in heart rate and atrioventricular conduction delays. Ponesimod has not been studied in patients taking concurrent QT prolonging drugs; however, QT prolonging drugs have been associated with TdP in patients with bradycardia Posaconazole: Major Avoid coadministration of azithromycin with posaconazole due to the increased risk of QT prolongation.
Posaconazole has been associated with prolongation of the QT interval as well as rare cases of TdP. Pravastatin: Moderate Azithromycin has the potential to increase pravastatin exposure when used concomitantly.
Primaquine: Major Avoid coadministration of azithromycin with primaquine due to the increased risk of QT prolongation. Primaquine has the potential for QT interval prolongation. Probenecid; Colchicine: Moderate Caution is warranted with the concomitant use of colchicine and azithromycin as increased colchicine concentrations may occur.
Procainamide: Major Avoid coadministration of azithromycin with procainamide due to the increased risk of QT prolongation. Procainamide is associated with a well-established risk of QT prolongation and TdP. Prochlorperazine: Major Avoid coadministration of azithromycin with prochlorperazine due to the increased risk of QT prolongation.
Prochlorperazine is associated with a possible risk for QT prolongation. Theoretically, prochlorperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. Promethazine: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation.
Promethazine; Dextromethorphan: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. Promethazine; Phenylephrine: Major Avoid coadministration of azithromycin with promethazine due to the increased risk of QT prolongation. Propafenone: Major Avoid coadministration of azithromycin with propafenone due to the increased risk of QT prolongation.
Protriptyline: Major Avoid coadministration of azithromycin with tricyclic antidepressants TCAs due to the increased risk of QT prolongation. Quetiapine: Major Avoid coadministration of azithromycin with quetiapine due to the increased risk of QT prolongation. Limited data, including some case reports, suggest that quetiapine may be associated with a significant prolongation of the QTc interval in rare instances.
Quinidine: Major Avoid coadministration of azithromycin with quinidine due to the increased risk of QT prolongation. Quinine: Major Avoid coadministration of azithromycin with quinine due to the increased risk of QT prolongation.
Quinine has been associated with QT prolongation and rare cases of TdP. Ranolazine: Major Avoid coadministration of azithromycin with ranolazine due to the increased risk of QT prolongation. Ranolazine is associated with dose- and plasma concentration-related increases in the QTc interval.
Although there are no studies examining the effects of ranolazine in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation.
Relugolix: Major Avoid coadministration of azithromycin with relugolix due to the increased risk of QT prolongation. Relugolix; Estradiol; Norethindrone acetate: Major Avoid coadministration of azithromycin with relugolix due to the increased risk of QT prolongation.
Ribociclib: Major Avoid coadministration of azithromycin with ribociclib due to the increased risk of QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. The ribociclib ECG changes occurred within the first four weeks of treatment and were reversible with dose interruption. Ribociclib; Letrozole: Major Avoid coadministration of azithromycin with ribociclib due to the increased risk of QT prolongation. Rilpivirine: Major Avoid coadministration of azithromycin with rilpivirine due to the increased risk of QT prolongation.
Risperidone: Major Avoid coadministration of azithromycin with risperidone due to the increased risk of QT prolongation. Romidepsin: Major Avoid coadministration of azithromycin with romidepsin due to the increased risk of QT prolongation. Romidepsin has been reported to prolong the QT interval. Salmeterol: Major Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of QT prolongation.
Saquinavir: Major Avoid coadministration of azithromycin with saquinavir boosted with ritonavir due to the increased risk of QT prolongation. Saquinavir boosted with ritonavir increases the QT interval in a dose-dependent fashion, which may increase the risk for serious arrhythmias such as TdP.
Segesterone Acetate; Ethinyl Estradiol: Moderate It would be prudent to recommend alternative or additional contraception when oral contraceptives OCs are used in conjunction with antibiotics. Selpercatinib: Major Avoid coadministration of azithromycin and selpercatinib due to the risk of additive QT prolongation. Monitor ECG and electrolytes and avoid other non-essential QT prolonging drugs if use together is required.
Concentration-dependent QT prolongation has been observed with selpercatinib therapy. Sertraline: Major Avoid coadministration of azithromycin with sertraline due to the increased risk of QT prolongation. Sertraline's FDA-approved labeling recommends avoiding concomitant use with drugs known to prolong the QTc interval; however, the risk of sertraline-induced QT prolongation is generally considered to be low in clinical practice.
Its effect on QTc interval is minimal typically less than 5 msec , and the drug has been used safely in patients with cardiac disease e.
Sevoflurane: Major Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of QT prolongation. Short-acting beta-agonists: Major Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of QT prolongation. Siponimod: Major Avoid coadministration of azithromycin with siponimod due to the increased risk of QT prolongation. Siponimod therapy prolonged the QT interval at recommended doses in a clinical study. Sodium picosulfate; Magnesium oxide; Anhydrous citric acid: Major Prior or concomitant use of antibiotics with sodium picosulfate; magnesium oxide; anhydrous citric acid may reduce efficacy of the bowel preparation as conversion of sodium picosulfate to its active metabolite bis- p-hydroxy-phenyl -pyridylmethane BHPM is mediated by colonic bacteria.
If possible, avoid coadministration. Certain antibiotics i. Therefore, these antibiotics should be taken at least 2 hours before and not less than 6 hours after the administration of sodium picosulfate; magnesium oxide; anhydrous citric acid solution. Solifenacin: Major Avoid coadministration of azithromycin with solifenacin due to the increased risk of QT prolongation. Solifenacin has been associated with dose-dependent prolongation of the QT interval.
TdP has been reported with postmarketing use, although causality was not determined. Sorafenib: Major Avoid coadministration of azithromycin with sorafenib due to the increased risk of QT prolongation. An interruption or discontinuation of sorafenib therapy may be necessary if QT prolongation occurs. Sorafenib is also associated with QTc prolongation.
0コメント